Now Playing
Opinion|Videos|October 25, 2024
Bringing CSU Back Under The House of Dermatology
Key Takeaways
- CSU primarily affects individuals aged 20 to 40, with a prevalence of 0.5% to 1% in the general population.
- Women are twice as likely to be affected by CSU compared to men.
Panelists discuss how chronic spontaneous urticaria (CSU) affects approximately 0.5% to 1% of the population, predominantly impacting women and often presenting with variable wheals and angioedema.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you give a general overview of CSU prevalence, clinical manifestations, and common patient characteristics?
- Incidence: Peak incidence between the ages of 20 and 40 years, lasting lasting 1 to 5 years in most patients, but longer in severe cases.
- Prevalence: Condition affects between 0.5% and 1% of the general population
- Women are affected twice as much often as men.
- How do the wheals/hives and/or angioedema typically appear for patients, and how can these symptoms vary by individual?
Advertisement
Related to this article
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
3
Asundexian Safely Reduces Ischemic Stroke Risk Regardless of Infarct Patterns on MRI
4
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
5